

Important Safety Information for Patients Receiving

Lunsumio (mosunetuzumab)

Patient Card



- Please carry this card with you at all times while you are receiving Lunsumio (mosunetuzumab).
- Show this card to any doctor involved in your care.
- Seek medical attention if you experience side effects.



Patient / Caregiver's Contact

Patient's name and contact: _____

Date of Lunsumio (mosunetuzumab) initiation: _____

Caregiver's name: _____

Caregiver's phone number: _____

Prescribing Doctor's Contact



Prescribing Doctor's name: _____

Prescribing Doctor's phone number: _____

For more information about Lunsumio (mosunetuzumab), please refer to the local package insert. Please report any side effects to Roche Patient Safety at hong_kong.drug_safety@roche.com. By reporting side effects, you can help to provide more information on the safety of this medicine.

Information for the Patient/Caregiver

Contact your Doctor or get emergency help **right away** if you have **any** of these symptoms:

Cytokine Release Syndrome (CRS) symptoms to monitor for:

- Fever (100.4°F /38°C or higher)
- Fast or irregular heartbeat
- Chills or shaking chills
- Confusion
- Severe fatigue or weakness
- Difficulty breathing
- Dizziness or light-headedness
- Fainting or blurred vision
- Cold or pale clammy skin
- Headache

Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) symptoms to monitor for:

- Confusion or disorientation
- Hallucinations (seeing, hearing or feeling things that are not there)
- Seizures
- Not being able to concentrate (difficulty staying awake)
- Problems with language (difficulty with speech or change in speech)
- Problems with judgement (change in thinking)
- Problems with memory

Information for the Treating Doctor

This patient has received Lunsumio (mosunetuzumab) - which may cause **Cytokine Release Syndrome (CRS)** and **Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)**.

- Evaluate the patient immediately and treat symptoms.
- If CRS is suspected, please refer to section 2.4 of the local package insert for instructions on CRS management.
- If ICANS is suspected, please refer to section 2.4 of the local package insert for instructions on ICANS management.
- **Contact the prescribing doctor** when possible - they may need to modify the next infusion of Lunsumio (mosunetuzumab).